Immunomodulation through secretion of anti-inflammatory cytokines and suppression of lymphocyte proliferation

Immunomodulation through the secretion of anti-inflammatory cytokines and the suppression of lymphocyte proliferation is a complex biological process rather than a single molecular target. It is the primary mechanism of action for several advanced therapeutic medicinal products, most notably Mesenchymal Stem Cells (MSCs) and Regulatory T cells (Tregs). These entities exert their therapeutic effects by producing a cocktail of paracrine factors, including Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-beta), which collectively dampen the activity of effector immune cells and arrest the cell cycle of proliferating lymphocytes. This multifaceted approach is particularly effective in treating conditions characterized by immune dysregulation, such as Graft-versus-Host Disease (GvHD), Crohn's disease, and various autoimmune disorders. Because it involves multiple pathways and cell-to-cell interactions, it offers a broader therapeutic window than single-target inhibitors but also presents challenges in standardization and potency assay development.

Other names

MSC-mediated immunomodulationTreg-mediated immunosuppressionParacrine immunomodulationCytokine-mediated lymphocyte suppression

This process involves the release of immunosuppressive factors such as IL-10, TGF-beta, and PGE2, which inhibit the activation and expansion of T cells, B cells, and NK cells while promoting the induction of regulatory T cells.